Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 4 1

Status

Completed 8Terminated 4Recruiting 4Withdrawn 2Unknown 1

Sponsor Class

OTHER_GOV 1OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1

Conditions

Opportunistic Infections 1Inflammation 1Hodgkin Disease 1Epstein-Barr Virus Infections 1Cytomegalovirus Infections 1Coinfection 1Acquired Immunodeficiency Syndrome 1

Interventions

Cyclophosphamide 129Cisplatin 119Radiotherapy 115pembrolizumab 111Carboplatin 97Paclitaxel 96Gemcitabine 96Magnetic Resonance Spectroscopy 80Nivolumab 76Bevacizumab 76Fluorouracil 74Dexamethasone 73Radiosurgery 66Docetaxel 59Rituximab 58Leucovorin 57Oxaliplatin 55Capecitabine 55Biopsy 53Doxorubicin 52fludarabine 51Drug Therapy 45durvalumab 44Cytarabine 44Etoposide 42fludarabine phosphate 40Pemetrexed 40Radiation 39atezolizumab 36Surveys and Questionnaires 36

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Ritonavir × Clear all
NCT01165645 2022-12-01

Lopinavir and Ritonavir in Improving Immune Response to Vaccines in Patients With Complete Remission Following A Bone Marrow Transplant for Hodgkin Lymphoma

Mayo Clinic

Phase NA Withdrawn
Lymphoid

Hodgkin Disease

NCT04183738 2020-11-10

i2-D²EFT

Kirby Institute

Phase 4 Withdrawn

Acquired Immunodeficiency Syndrome, Cytomegalovirus Infections, Inflammation, Opportunistic Infections, Epstein-Barr Virus Infections, Coinfection

Data powered by HemOnc (CC BY 4.0) Colophon âš¡